Ophthalmology Daily Report: 01/25/2024

A phase 3, global, randomized, double-masked, active comparator-controlled study investigated the effect of faricimab compared with aflibercept in 553 and 729 patients with macular edema due to retinal vein occlusion and found faricimab to be noninferior to aflibercept in improving best-corrected visual acuity at 24 weeks (1). Faricimab was well tolerated with a comparable safety profile to aflibercept.

Reference

Tadayoni R, Paris LP, Danzig CJ, Abreu F, Khanani AM, Brittain C, Lai TYY, Haskova Z, Sakamoto T, Kotecha A, Schlottmann PG, Liu Y, Seres A, Retiere AC, Willis JR, Yoon YH; BALATON and COMINO Investigators. Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials. Ophthalmology. 2024 Jan 25:S0161-6420(24)00090-3. doi: 10.1016/j.ophtha.2024.01.029. Epub ahead of print. PMID: 38280653.